Relamorelin
Also known as: RM-131, BIM-28131, Ghrelin analog
Relamorelin (also called RM-131 or BIM-28131) is an investigational ghrelin analog in the Growth Hormone Secretagogue class. Relamorelin is a synthetic pentapeptide agonist at growth hormone secretagogue receptor 1a, developed principally for its gastrointestinal rather than endocrine activity. Ghrelin receptors are expressed on enteric neurons, and their activation accelerates gastric emptying and increases antral contractility.
For research use only.
Key Facts
- CAS
- 661472-41-9
- Molecular Weight (MW)
- 790.97 g/mol
- Half-life
- Not firmly established in public sources; studied as short-acting sc peptide
- FDA status
- Investigational New Drug (IND)
- Administration Route
- Subcutaneous
- Frequency
- Per study
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- GHSR
Research summary
Investigational pentapeptide ghrelin receptor agonist developed principally for its gastrointestinal rather than endocrine effects. Ghrelin receptors on enteric neurons accelerate gastric emptying when activated, and relamorelin has been studied mainly in diabetic gastroparesis, where delayed emptying drives the symptoms. Clinical development has been mixed and it is not FDA-approved for any indication.
Peptide Library's Relamorelin profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Per study
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
- Timing Notes
- Investigational for diabetic gastroparesis and GI motility disorders
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Relamorelin is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C43H50N8O5S |
|---|---|
| Molecular weight | 790.97 g/mol |
| CAS number | 661472-41-9 |
| Half-life | Not firmly established in public sources; studied as short-acting sc peptide |
| Appearance | Lyophilized powder or solution (investigational sc) |
| Formulation | Lyophilized Powder |
| PubChem CID | 44251769 |
| ChEMBL | CHEMBL4297525 |
| DrugBank | DB12678 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Relamorelin is a synthetic pentapeptide agonist at growth hormone secretagogue receptor 1a, developed principally for its gastrointestinal rather than endocrine activity. Ghrelin receptors are expressed on enteric neurons, and their activation accelerates gastric emptying and increases antral contractility. Relamorelin was engineered for greater potency and metabolic stability than native ghrelin and has been studied in diabetic gastroparesis, where delayed gastric emptying underlies the symptoms. It raises growth hormone as a class effect, but that is incidental to its intended use. It is investigational and not approved.
Origin
Synthetic ghrelin-mimetic pentapeptide.
Targets
Studies
- A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned
- Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study
- Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety
- Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials
- Relamorelin for the treatment of gastrointestinal motility disorders
Regulatory & research status
Relamorelin has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Banned in Sport |
| Library classification | Clinical Trial |
Benefits
Relamorelin side effects
Side Effects
- Hyperglycemia
- Hunger
- GI effects
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Relamorelin: frequently asked questions
What is Relamorelin?
Investigational pentapeptide ghrelin receptor agonist developed principally for its gastrointestinal rather than endocrine effects. Ghrelin receptors on enteric neurons accelerate gastric emptying when activated, and relamorelin has been studied mainly in diabetic gastroparesis, where delayed emptying drives the symptoms. Clinical development has been mixed and it is not FDA-approved for any indication.
How does Relamorelin work?
Relamorelin is a synthetic pentapeptide agonist at growth hormone secretagogue receptor 1a, developed principally for its gastrointestinal rather than endocrine activity. Ghrelin receptors are expressed on enteric neurons, and their activation accelerates gastric emptying and increases antral contractility.
Is Relamorelin FDA approved?
No. Relamorelin is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What is the half-life of Relamorelin?
Reported half-life for Relamorelin is Not firmly established in public sources; studied as short-acting sc peptide. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Relamorelin banned in sport?
Relamorelin is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.
What peptides are similar to Relamorelin?
Compounds most often compared with Relamorelin include MK-677, Macimorelin, Anamorelin and Tabimorelin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned — Parkinsonism Relat Disord, 2017External reference
- Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study — Gastroenterology, 2017External reference
- Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety — Cureus, 2023External reference
- Pharmacological Approaches to Diabetic Gastroparesis: A systematic review of randomised clinical trials — Sultan Qaboos Univ Med J, 2019External reference
- Relamorelin for the treatment of gastrointestinal motility disorders — Expert Opin Investig Drugs, 2017External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Relamorelin profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Relamorelin research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →